H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics to $40 from $38 and keeps a Buy rating on the shares following the Q2 report. The firm says key readouts are expected in Q4 and and Q1 of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics announces publication of clinical data on JNJ-2113
- Protagonist Therapeutics appoints Newman Yeilding as chief scientific advisor
- Protagonist Therapeutics price target raised to $51 from $41 at BTIG
- Protagonist Therapeutics to replace Encore Wire in S&P 600 at open on 7/3
- 3 Best Stocks to Buy Now, 6/17/2024, According to Top Analysts